

Stefan Agewall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5718323/publications.pdf>

Version: 2024-02-01

225
papers

63,651
citations

38742

50
h-index

2127

203
g-index

236
all docs

236
docs citations

236
times ranked

52891
citing authors

#	ARTICLE	IF	CITATIONS
1	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2018, 39, 119-177.	2.2	7,100
2	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2018, 39, 3021-3104.	2.2	6,826
3	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Heart Journal</i> , 2016, 37, 2893-2962.	2.2	5,689
4	2017 ESC/EACTS Guidelines for the management of valvular heart disease. <i>European Heart Journal</i> , 2017, 38, 2739-2791.	2.2	5,142
5	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2019, 40, 87-165.	2.2	4,537
6	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. <i>European Heart Journal</i> , 2020, 41, 407-477.	2.2	4,210
7	ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2011, 32, 2999-3054.	2.2	2,995
8	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>European Heart Journal</i> , 2011, 32, 1769-1818.	2.2	2,767
9	Fourth universal definition of myocardial infarction (2018). <i>European Heart Journal</i> , 2019, 40, 237-269.	2.2	2,687
10	Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2010, 31, 2501-2555.	2.2	2,649
11	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2014, 35, 3033-3080.	2.2	2,591
12	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Heart Journal</i> , 2018, 39, 213-260.	2.2	2,246
13	2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>European Heart Journal</i> , 2018, 39, 3165-3241.	2.2	1,396
14	ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2011, 32, 2851-2906.	2.2	1,394
15	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. <i>European Journal of Heart Failure</i> , 2017, 19, 9-42.	7.1	920
16	Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. <i>European Heart Journal</i> , 2009, 30, 2769-2812.	2.2	735
17	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2016, 23, NP1-NP96.	1.8	683
18	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. <i>Europace</i> , 2015, 17, euv319.	1.7	635

#	ARTICLE	IF	CITATIONS
19	ESC/EAS Guidelines for the management of dyslipidaemias. <i>Atherosclerosis</i> , 2011, 217, 3-46.	0.8	561
20	Contemporary Diagnosis and Management of Patients With Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2019, 139, e891-e908.	1.6	519
21	ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. <i>European Heart Journal</i> , 2017, 38, ehw149.	2.2	511
22	Troponin elevation in coronary vs. non-coronary disease. <i>European Heart Journal</i> , 2011, 32, 404-411.	2.2	502
23	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 4-90.	1.4	402
24	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia. <i>Annals of Internal Medicine</i> , 2015, 163, 40-51.	3.9	357
25	The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials. <i>European Heart Journal</i> , 2014, 35, 2001-2009.	2.2	274
26	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 34-78.	1.4	261
27	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk. <i>Circulation</i> , 2020, 142, 621-642.	1.6	232
28	Usefulness of Microalbuminuria in Predicting Cardiovascular Mortality in Treated Hypertensive Men With and Without Diabetes Mellitus. <i>American Journal of Cardiology</i> , 1997, 80, 164-169.	1.6	175
29	Chlamydia pneumoniae but Not Cytomegalovirus Antibodies Are Associated With Future Risk of Stroke and Cardiovascular Disease. <i>Stroke</i> , 1999, 30, 299-305.	2.0	172
30	Matrix Metalloproteinases in Atherothrombosis. <i>Progress in Cardiovascular Diseases</i> , 2010, 52, 410-428.	3.1	164
31	Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. <i>European Heart Journal</i> , 2013, 34, 1708-1713.	2.2	159
32	Endothelium-derived hyperpolarizing factor in vascular physiology and cardiovascular disease. <i>Atherosclerosis</i> , 2009, 202, 330-344.	0.8	148
33	Antiarrhythmic drugs: clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). <i>Europace</i> , 2016, 20, 731-732an.	1.7	144
34	Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC: Figure A1. <i>European Heart Journal</i> , 2015, 36, 2677-2680.	2.2	131
35	Troponin and exercise. <i>International Journal of Cardiology</i> , 2016, 221, 609-621.	1.7	120
36	Interrelation between the extent of atherosclerosis in the thoracic aorta, carotid intima-media thickness and the extent of coronary artery disease. <i>Atherosclerosis</i> , 2005, 179, 311-316.	0.8	116

#	ARTICLE	IF	CITATIONS
37	Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 180-188.	3.0	113
38	Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal</i> , 2016, 37, 1015-1023.	2.2	109
39	Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 812-817.	0.9	101
40	Carotid Artery Wall Intima-Media Thickness Is Associated With Insulin-Mediated Glucose Disposal in Men at High and Low Coronary Risk. <i>Stroke</i> , 1995, 26, 956-960.	2.0	90
41	The Impact of Renal Dysfunction on Outcomes in the ExTRACT-TIMI 25 Trial. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2249-2255.	2.8	87
42	Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High-Risk Myocardial Infarction Database Initiative. <i>European Journal of Heart Failure</i> , 2015, 17, 1144-1151.	7.1	84
43	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). <i>European Journal of Preventive Cardiology</i> , 2017, 24, 4-40.	1.8	83
44	Non-invasive assessment of endothelial function – relation between vasodilatory responses in skin microcirculation and brachial artery. <i>Clinical Physiology and Functional Imaging</i> , 2004, 24, 317-322.	1.2	77
45	Inflammatory markers and extent and progression of early atherosclerosis: Meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 194-205.	1.8	74
46	Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. <i>International Journal of Cardiology</i> , 2013, 167, 1772-1782.	1.7	67
47	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). <i>Europace</i> , 2017, 19, euw242.	1.7	67
48	COPD Predicts Mortality in HF: The Norwegian Heart Failure Registry. <i>Journal of Cardiac Failure</i> , 2010, 16, 225-229.	1.7	65
49	Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 232.	3.5	50
50	Randomized evaluation of beta blocker and ACE-inhibitor/angiotensin receptor blocker treatment in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA-BAT): Rationale and design. <i>American Heart Journal</i> , 2021, 231, 96-104.	2.7	49
51	Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management – a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017, 38, ehv676.	2.2	48
52	Reduced quality of life after myocardial infarction in women compared with men. <i>Clinical Cardiology</i> , 2004, 27, 271-274.	1.8	47
53	Risk Factors and Markers for Acute Myocardial Infarction With Angiographically Normal Coronary Arteries. <i>American Journal of Cardiology</i> , 2015, 116, 838-844.	1.6	47
54	Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 171-180.	3.0	46

#	ARTICLE	IF	CITATIONS
55	Early Comprehensive Cardiovascular Magnetic Resonance Imaging in Patients With Myocardial Infarction With Nonobstructive Coronary Arteries. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1774-1783.	5.3	46
56	Chlamydia pneumoniae Seropositivity Is Associated With Carotid Artery Intima-Media Thickness. <i>Stroke</i> , 2000, 31, 1526-1531.	2.0	45
57	Effect of Angiotensin-Converting Enzyme Inhibition on One-Year Mortality and Frequency of Repeat Acute Myocardial Infarction in Patients With Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2010, 105, 1229-1234.	1.6	45
58	Matrix metalloproteinases and cardiovascular disease The opinions expressed in this article are not necessarily those of the Editors of the <i>European Heart Journal</i> or of the <i>European Society of Cardiology</i> . <i>European Heart Journal</i> , 2006, 27, 121-122.	2.2	40
59	Comprehensive efforts to increase adherence to statin therapy. <i>European Heart Journal</i> , 2017, 38, ehw628.	2.2	40
60	Acute dilatation to phytoestrogens and estrogen receptor subtypes expression in small arteries from women with coronary heart disease. <i>Atherosclerosis</i> , 2008, 196, 49-58.	0.8	39
61	Effect of Myocardial Infarction With Nonobstructive Coronary Arteries on Physical Capacity and Quality-of-Life. <i>American Journal of Cardiology</i> , 2017, 120, 341-346.	1.6	39
62	Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 230-236.	3.0	39
63	Early Prediction of Increased Arterial Stiffness in Patients with Chronic Inflammation: A 15-year Followup Study of 108 Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 606-612.	2.0	37
64	Prevalence of Anxiety and Depression Symptoms in Patients with Myocardial Infarction with Non-Obstructive Coronary Arteries. <i>American Journal of Medicine</i> , 2018, 131, 1118-1124.	1.5	37
65	Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the <i>European Society of Cardiology</i> . <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 108-118.	3.0	35
66	Cardiac troponin I for prediction of clinical outcomes and cardiac function through 3-month follow-up after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2015, 169, 257-265.e1.	2.7	33
67	Atherosclerotic Disease in the Femoral Artery in Hypertensive Patients at High Cardiovascular Risk. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1996, 16, 971-977.	2.4	33
68	Risk Factors for Myocardial Infarction With Normal Coronary Arteries and Myocarditis Compared With Myocardial Infarction With Coronary Artery Stenosis. <i>Angiology</i> , 2012, 63, 500-503.	1.8	32
69	Troponins in heart failure. <i>Clinica Chimica Acta</i> , 2015, 443, 78-84.	1.1	32
70	Morphine in the treatment of acute pulmonary oedema – Why?. <i>International Journal of Cardiology</i> , 2016, 202, 870-873.	1.7	32
71	Stroke Was Predicted by Dimensions of Quality of Life in Treated Hypertensive Men. <i>Stroke</i> , 1998, 29, 2329-2333.	2.0	30
72	ESC guidelines adherence is associated with improved survival in patients from the Norwegian Heart Failure Registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 31-36.	3.0	30

#	ARTICLE	IF	CITATIONS
73	Multiple Risk Intervention in High-Risk Hypertensive Patients. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1996, 16, 462-470.	2.4	29
74	Atherosclerosis: Recent trials, new targets and future directions. <i>International Journal of Cardiology</i> , 2015, 192, 72-81.	1.7	28
75	Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure. <i>Clinical Research in Cardiology</i> , 2017, 106, 711-721.	3.3	27
76	Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 86-93.	3.0	27
77	Microalbuminuria and intima-media thickness of the carotid artery in clinically healthy men. <i>Atherosclerosis</i> , 2002, 164, 161-166.	0.8	26
78	Is Impaired Flow-Mediated Dilatation of the Brachial Artery a Cardiovascular Risk Factor?. <i>Current Vascular Pharmacology</i> , 2003, 1, 107-109.	1.7	26
79	Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. <i>Heart Failure Reviews</i> , 2021, 26, 1421-1435.	3.9	26
80	Atorvastatin normalizes endothelial function in healthy smokers. <i>Clinical Science</i> , 2006, 111, 87-91.	4.3	25
81	Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 104-114.	3.0	25
82	Post-occlusion brachial artery vasodilatation after ischaemic handgrip exercise is nitric oxide mediated. <i>Clinical Physiology and Functional Imaging</i> , 2002, 22, 18-23.	1.2	24
83	Gender differences among Norwegian patients with heart failure. <i>International Journal of Cardiology</i> , 2011, 146, 354-358.	1.7	24
84	Relationship between left ventricular ejection fraction and mortality after myocardial infarction complicated by heart failure or left ventricular dysfunction. <i>International Journal of Cardiology</i> , 2018, 272, 260-266.	1.7	24
85	The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 85-99.	3.0	23
86	Circulating levels of autoantibodies to oxidized low-density lipoprotein and C-reactive protein levels correlate with endothelial function in resistance arteries in men with coronary heart disease. <i>Heart and Vessels</i> , 2009, 24, 90-95.	1.2	22
87	Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis. <i>Clinical Research in Cardiology</i> , 2022, 111, 428-439.	3.3	22
88	Evaluation of point-of-care test systems using the new definition of myocardial infarction. <i>Clinical Biochemistry</i> , 2003, 36, 27-30.	1.9	21
89	Carvedilol Compared With Metoprolol Succinate in the Treatment and Prognosis of Patients With Stable Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 887-896.	3.9	20
90	Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. <i>PLoS ONE</i> , 2017, 12, e0169830.	2.5	20

#	ARTICLE	IF	CITATIONS
91	Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate. <i>European Heart Journal Supplements</i> , 2019, 21, A28-A33.	0.1	20
92	Endothelial function in conduit and resistance arteries in men with coronary disease. <i>Atherosclerosis</i> , 2006, 184, 130-136.	0.8	19
93	Acute and stable coronary heart disease: different risk factors. <i>European Heart Journal</i> , 2008, 29, 1927-1929.	2.2	19
94	New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint. <i>International Journal of Cardiology</i> , 2015, 196, 133-138.	1.7	19
95	Increased Inflammatory Activity in Patients 3 Months after Myocardial Infarction with Nonobstructive Coronary Arteries. <i>Clinical Chemistry</i> , 2019, 65, 1023-1030.	3.2	18
96	Epidemiology and long-term outcome in outpatients with chronic heart failure in Northwestern Europe. <i>Heart</i> , 2019, 105, 1252-1259.	2.9	18
97	Adherence to guidelines and registry data. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 183-184.	3.0	17
98	ST-segment elevation and cardiac magnetic resonance imaging findings in myocardial infarction with non-obstructive coronary arteries. <i>International Journal of Cardiology</i> , 2019, 287, 128-131.	1.7	17
99	Subclinical Atherosclerosis, Endothelial Function, and Serum Inflammatory Markers in Chronic Kidney Disease Stages 3 to 4. <i>Angiology</i> , 2014, 65, 443-449.	1.8	16
100	Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal</i> , 2018, 39, 2274-2281.	2.2	16
101	Questions and answers on diagnosis and management of patients with Peripheral Arterial Diseases: a companion document of the 2017 ESC Guidelines for the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). <i>European Heart Journal</i> , 2018, 39, e35-e41.	2.2	16
102	Tumor necrosis factor inhibitors are associated with reduced complement activation in spondylarthropathies: An observational study. <i>PLoS ONE</i> , 2019, 14, e0220079.	2.5	16
103	Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 47-54.	3.0	16
104	Intima-media complex of both the brachial artery and the common carotid artery are associated with left ventricular hypertrophy in patients with previous myocardial infarction. <i>Journal of Hypertension</i> , 2005, 23, 119-125.	0.5	15
105	Diagnostic value of high sensitive troponin T in chest pain patients with no persistent ST-elevations. <i>Scandinavian Cardiovascular Journal</i> , 2011, 45, 198-204.	1.2	15
106	Prognostic value of combining high sensitive troponin T and N-terminal pro B-type natriuretic peptide in chest pain patients with no persistent ST-elevation. <i>Clinica Chimica Acta</i> , 2012, 413, 933-937.	1.1	15
107	Esomeprazole for Prevention and Resolution of Upper Gastrointestinal Symptoms in Patients Treated With Low-dose Acetylsalicylic Acid for Cardiovascular Protection. <i>Journal of Cardiovascular Pharmacology</i> , 2013, 61, 250-257.	1.9	15
108	New ESC/ EACTS Guidelines for the management of atrial fibrillation. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 3, pvw038.	3.0	15

#	ARTICLE	IF	CITATIONS
109	Medical Misinformation: Vet the Message!. Journal of the American Heart Association, 2019, 8, e011838.	3.7	15
110	Risk Factors That Predict Development of Microalbuminuria in Treated Hypertensive Men. Angiology, 1996, 47, 963-972.	1.8	14
111	Impact of physical activity and body composition on heart function and morphology in middle-aged, abdominally obese women. Clinical Physiology and Functional Imaging, 2010, 30, 354-359.	1.2	14
112	Incremental value of a combination of cardiac troponin T, N-terminal pro-brain natriuretic peptide and C-reactive protein for prediction of mortality in end-stage renal disease. Scandinavian Journal of Urology and Nephrology, 2011, 45, 151-158.	1.4	14
113	The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 97-103.	3.0	14
114	Effect of tissue harmonic imaging and contrast upon between observer and test-retest reproducibility of left ventricular ejection fraction measurement in patients with heart failure. European Journal of Heart Failure, 2004, 6, 85-93.	7.1	13
115	Should oral glucose tolerance test be a routine examination after a myocardial infarction?. International Journal of Cardiology, 2004, 97, 21-24.	1.7	13
116	The burden of heart failure in the general population: a clearer and more concerning picture. Journal of Thoracic Disease, 2018, 10, S1934-S1937.	1.4	13
117	Plasma catecholamine levels in the acute and subacute stages of takotsubo syndrome: Results from the Stockholm myocardial infarction with normal coronaries 2 study. Clinical Cardiology, 2021, 44, 1567-1574.	1.8	13
118	Usefulness of Troponin Levels Below the Diagnostic Cut-Off Level for Acute Myocardial Infarction in Predicting Prognosis in Unselected Patients Admitted to the Coronary Care Unit. American Journal of Cardiology, 2007, 99, 1357-1359.	1.6	12
119	Expression of heat shock proteins and nitrotyrosine in small arteries from patients with coronary heart disease. Heart and Vessels, 2009, 24, 260-266.	1.2	12
120	Non-alcoholic fatty liver disease and cardiovascular disease. Atherosclerosis, 2012, 224, 324-325.	0.8	12
121	Relations of Serum COMP to Cardiovascular Risk Factors and Endothelial Function in Patients with Rheumatoid Arthritis Treated with Methotrexate and TNF- α Inhibitors. Journal of Rheumatology, 2012, 39, 1341-1347.	2.0	12
122	2-h postchallenge plasma glucose predicts cardiovascular events in patients with myocardial infarction without known diabetes mellitus. Cardiovascular Diabetology, 2012, 11, 93.	6.8	11
123	Morphine in acute heart failure. Journal of Thoracic Disease, 2017, 9, 1851-1854.	1.4	11
124	Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 82-92.	3.0	11
125	Personality Traits in Patients with Myocardial Infarction with Nonobstructive Coronary Arteries. American Journal of Medicine, 2019, 132, 374-381.e1.	1.5	11
126	Lipoprotein(a) was an independent predictor for major coronary events in treated hypertensive men. Clinical Cardiology, 2002, 25, 287-290.	1.8	10

#	ARTICLE	IF	CITATIONS
127	Echogenicity of the carotid intima-media complex and cardiovascular risk factors. <i>Clinical Physiology and Functional Imaging</i> , 2012, 32, 400-403.	1.2	10
128	Relationship Between Oxidized LDL, IgM, and IgG Autoantibodies to ox-LDL Levels With Recurrent Cardiovascular Events in Swedish Patients With Previous Myocardial Infarction. <i>Angiology</i> , 2014, 65, 932-936.	1.8	10
129	Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure - A multicenter propensity score matched analysis. <i>International Journal of Cardiology</i> , 2019, 289, 83-90.	1.7	10
130	Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 234-243.	1.8	10
131	Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 187-210.	3.0	10
132	Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 557-567.	3.0	10
133	Antirheumatic treatment is associated with reduced serum Syndecan-1 in Rheumatoid Arthritis. <i>PLoS ONE</i> , 2021, 16, e0253247.	2.5	10
134	troponin Elevation in Coronary Ischemia and Necrosis. <i>Current Atherosclerosis Reports</i> , 2014, 16, 396.	4.8	9
135	Effect of anti-rheumatic treatment on selenium levels in inflammatory arthritis. <i>Journal of Trace Elements in Medicine and Biology</i> , 2018, 49, 91-97.	3.0	9
136	Oral antiplatelet agents in ACS: from pharmacology to clinical differences. <i>Fundamental and Clinical Pharmacology</i> , 2011, 25, 564-571.	1.9	8
137	Amyotrophic lateral sclerosis (ALS), a novel rare cause of elevated plasma troponin T levels. <i>Clinical Laboratory</i> , 2011, 57, 615-8.	0.5	8
138	Prothrombin fragment 1+2 is associated with intima media thickness of the carotid artery in patients with myocardial infarction. <i>Thrombosis Research</i> , 2009, 124, 526-530.	1.7	7
139	Ultrasound and radiology surrogate endpoints in pharmacological studies. <i>Atherosclerosis</i> , 2012, 224, 12-24.	0.8	7
140	Morphine in myocardial infarction: balancing on the tight rope. <i>European Heart Journal</i> , 2016, 37, 253-255.	2.2	7
141	Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction. <i>American Heart Journal</i> , 2019, 215, 83-90.	2.7	7
142	Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 210-215.	3.0	7
143	The new definition of myocardial infarction-Can we use it?. <i>Clinical Cardiology</i> , 2005, 28, 77-80.	1.8	6
144	How should we evaluate an open artery in STEMI patients?. <i>European Heart Journal</i> , 2005, 26, 634-636.	2.2	6

#	ARTICLE	IF	CITATIONS
145	Disturbed glucose metabolism is associated with left ventricular dysfunction using tissue Doppler imaging in patients with myocardial infarction. <i>Clinical Physiology and Functional Imaging</i> , 2007, 27, 60-66.	1.2	6
146	Obstructive sleep apnea: no independent association to troponins. <i>Sleep and Breathing</i> , 2014, 18, 351-358.	1.7	6
147	Cardiovascular pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 1-1.	3.0	6
148	Plasma biomarker levels and non-obstructive coronary artery disease determined by coronary computed tomography angiography. <i>Clinical Physiology and Functional Imaging</i> , 2018, 38, 246-253.	1.2	6
149	Antiplatelet treatment in acute coronary syndrome. Still an issue. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 125-126.	3.0	6
150	All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System. <i>American Journal of Therapeutics</i> , 2019, 26, e671-e678.	0.9	6
151	Minimizing bleeding events. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 271-272.	3.0	6
152	Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, , .	3.0	6
153	Clopidogrel inhibits platelet aggregation in patients on aspirin with stable chronic angina pectoris. <i>International Journal of Cardiology</i> , 2008, 123, 195-196.	1.7	5
154	Some Aspects of Preventing Coronary Heart Disease. <i>Angiology</i> , 2012, 63, 17-23.	1.8	5
155	Low self-estimated quality of life after myocardial infarction and future cardiovascular risk. <i>International Journal of Cardiology</i> , 2012, 157, 128-129.	1.7	5
156	Neither endothelial function nor carotid artery intima-media thickness predicts coronary computed tomography angiography plaque burden in clinically healthy subjects: a cross-sectional study. <i>BMC Cardiovascular Disorders</i> , 2015, 15, 63.	1.7	5
157	Statins attenuate but do not eliminate the reverse epidemiology of total serum cholesterol in patients with non-ischemic chronic heart failure. <i>International Journal of Cardiology</i> , 2017, 238, 97-104.	1.7	5
158	Cardiovascular pharmacotherapy and real-world data. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 65-66.	3.0	5
159	Critical appraisal of the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 191-192.	3.0	5
160	The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 453-459.	3.0	5
161	Intima-Media Thickness of Common Carotid and Brachial Arteries and Prothrombin Fragment 1 + 2 Are Associated with Left Ventricular Diastolic Dysfunction in Patients with Myocardial Infarction. <i>Echocardiography</i> , 2010, 27, 651-658.	0.9	4
162	Myeloid-related protein-8/14 and C-reactive protein in individuals evaluated for obstructive sleep apnea. <i>Sleep Medicine</i> , 2014, 15, 762-768.	1.6	4

#	ARTICLE	IF	CITATIONS
163	New-onset atrial fibrillation after percutaneous coronary intervention with stent: Updated proposal of an algorithm for the choice of oral anticoagulant and its dose. <i>European Journal of Internal Medicine</i> , 2017, 40, e11-e12.	2.2	4
164	Unsolved issues in oral anticoagulation treatment in atrial fibrillation. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 60-61.	3.0	4
165	The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale. <i>Gerontology</i> , 2020, 66, 447-459.	2.8	4
166	Antirheumatic therapy is not associated with changes in circulating N-terminal pro-brain natriuretic peptide levels in patients with autoimmune arthritis. <i>PLoS ONE</i> , 2021, 16, e0253793.	2.5	4
167	Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 100-103.	3.0	4
168	Fysisk anstrengelse kan gi h�ye troponinverdier. <i>Tidsskrift for Den Norske L�geforening</i> , 2011, 131, 2226-2226.	0.2	4
169	Antirheumatic therapy is associated with reduced complement activation in rheumatoid arthritis. <i>PLoS ONE</i> , 2022, 17, e0264628.	2.5	4
170	Quality of life and insulin resistance in patients with coronary heart disease. <i>Coronary Artery Disease</i> , 2008, 19, 289-292.	0.7	3
171	Sick leave and a smoking ban. <i>European Heart Journal</i> , 2014, 35, 266-267.	2.2	3
172	End of story? Studies on prevention of reperfusion injury encounter perpetual defeats. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 46-47.	3.0	3
173	Focus on subpopulations of atrial fibrillation patients. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 131-132.	3.0	3
174	Hyperkalemia and Renin�Angiotensin�Aldosterone System Inhibitors Dose Therapy in Heart Failure With Reduced Ejection Fraction. <i>Cardiac Failure Review</i> , 2019, 5, 130-132.	3.0	3
175	Antiplatelet treatment in coronary syndrome. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 81-82.	3.0	3
176	Antiphospholipid antibodies in patients with myocardial infarction with and without obstructive coronary arteries. <i>Journal of Internal Medicine</i> , 2022, 291, 327-337.	6.0	3
177	Changes in diagnosing non-ST-segment elevation myocardial infarction after the introduction of a new high-sensitivity cardiac troponin T assay: a single-centre experience. <i>Clinical Laboratory</i> , 2012, 58, 1029-36.	0.5	3
178	Anticoagulation, atherosclerosis, and heart failure. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 1-2.	3.0	2
179	Adherence to guidelines, compliance to treatment, and treatment quality. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 189-190.	3.0	2
180	Old and new drugs in cardiovascular pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 1-2.	3.0	2

#	ARTICLE	IF	CITATIONS
181	Can we offer tailor-made pharmacological treatment of patients with acute coronary syndrome?. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 201-202.	3.0	2
182	The Association of Smoking with Hospitalization and Mortality Differs According to Sex in Patients with Heart Failure Following Myocardial Infarction. Journal of Women's Health, 2022, 31, 310-320.	3.3	2
183	Snus is not Harmless!. European Journal of Epidemiology, 2003, 19, 819.	5.7	1
184	Levosimendan: Perpetuum mobile?. European Heart Journal, 2007, 28, 515-515.	2.2	1
185	Interpreting clinical trials: the "Beautiful" case. Fundamental and Clinical Pharmacology, 2009, 23, 261-262.	1.9	1
186	Conventional treatment after myocardial infarction in routine clinical practice results in regression of left common carotid intima-media thickness. Clinical Physiology and Functional Imaging, 2014, 34, 322-326.	1.2	1
187	Heart rate prediction of outcome in heart failure following myocardial infarction depend on heart rhythm status an analysis from the high-risk myocardial infarction database initiative. International Journal of Cardiology, 2017, 249, 274-281.	1.7	1
188	Metabolic control, anticoagulation, and gender aspects. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 125-126.	3.0	1
189	European Heart Journal " Cardiovascular Pharmacotherapy. European Heart Journal, 2017, 38, 3251-3251.	2.2	1
190	New input on antiplatelet treatment and registry studies. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 129-130.	3.0	1
191	Lipids and antithrombotic treatment. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 71-71.	3.0	1
192	MSc in clinical trials: a new flagship Working Group project. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 284-284.	3.0	1
193	Different aspects of giving the optimal antiplatelet treatment. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 169-170.	3.0	1
194	Adherence to pharmacological treatment: how can we improve?. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 261-262.	3.0	1
195	Fluoroquinolone use and valvular heart disease: is the jury still out?. European Heart Journal, 2021, 42, 2909-2911.	2.2	1
196	More knowledge about atrial fibrillation, still we need to learn. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 361-362.	3.0	1
197	Atrial fibrillation in registries. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 1-2.	3.0	1
198	OUP accepted manuscript. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 1-3.	3.0	1

#	ARTICLE	IF	CITATIONS
199	Focus on blood pressure and risk factor intervention. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 339-340.	3.0	1
200	Focus on different aspects of atrial fibrillation. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 323-324.	3.0	1
201	Urinary albumin excretion and insulin metabolism in clinically healthy 58-year-old men. Metabolism: Clinical and Experimental, 2002, 51, 750-753.	3.4	0
202	Gender issues in cardiovascular medicine. Gynecological Endocrinology, 2007, 23, 363-365.	1.7	0
203	Thyroid Dysfunction in Patients With Myocardial Infarction With Normal Coronary Arteries. Angiology, 2013, 64, 245-246.	1.8	0
204	The early diastolic myocardial velocity: a marker of increased risk in patients with coronary heart disease. Clinical Physiology and Functional Imaging, 2014, 34, 389-396.	1.2	0
205	European Heart Journal " CVP: what is next?. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 73-73.	3.0	0
206	Cardiovascular Pharmacotherapy is moving!. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 149-149.	3.0	0
207	Starting up a new Journal within the European Heart Journal Family. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 213-213.	3.0	0
208	European Heart Journal " Cardiovascular Pharmacotherapy: a new journal within the European Heart Journal family. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 1-1.	3.0	0
209	How to save six million people per year. Atherosclerosis, 2015, 240, 387-388.	0.8	0
210	The application to MEDLINE from European Heart Journal-Cardiovascular Pharmacotherapy has been accepted!. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 207-208.	3.0	0
211	Cardiovascular pharmacotherapy. International Journal of Cardiology, 2016, 224, 412-415.	1.7	0
212	Update from EHJ CVP. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 77-78.	3.0	0
213	News from EHJ CVP. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 141-141.	3.0	0
214	Second year of a journal. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 1-2.	3.0	0
215	Annual report of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 3-4.	3.0	0
216	European Heart Journal " Cardiovascular Pharmacotherapy has received its first Impact Factor of 6.723. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 183-184.	3.0	0

#	ARTICLE	IF	CITATIONS
217	European Heart Journal â€“ Cardiovascular Pharmacotherapy: now accepted for an official Impact Factor. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 59-59.	3.0	0
218	EJ Cardiovascular Pharmacotherapy has Impact Factor. European Heart Journal, 2019, 40, 572-572.	2.2	0
219	Ivabradine for heart failure: regulatory differences in Europe and United States. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 119-121.	3.0	0
220	AB0343â€¦ANTIRHEUMATIC THERAPY IS NOT ASSOCIATED WITH CHANGES IN CIRCULATING N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE (NT-PROBNP) LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
221	Focus on pharma in acute coronary syndrome. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 1-2.	3.0	0
222	Unsolved pharmacological issues with cardiology. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 461-462.	3.0	0
223	Re: Ulike retningslinjer for behandling av prostatakref. Tidsskrift for Den Norske Laegeforening, 2015, 135, 1337-1337.	0.2	0
224	Optimizing individual heart failure treatment. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, , .	3.0	0
225	Future of Antithrombotic Therapy for Heart Failure with Coronary Artery Disease. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, , .	3.0	0